Lipid Nanoparticle CD47 Coating Evades Macrophage Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNA-based therapeutic delivery systems face challenges in targeted delivery and off-target effects, particularly in bypassing the immune response and minimizing uptake by macrophages, which hinders their biomedical translation and utility.
Innovation Solution
A composition comprising a therapeutic agent and a delivery vehicle with a moiety that inhibits macrophage uptake, such as a CD47 polypeptide or lipid nanoparticle (LNP) conjugated with a targeting moiety, specifically designed to evade immune uptake and target specific cells like endothelial or immune cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If lipid nanoparticles (LNPs) are used to deliver therapeutic agents, then delivery efficiency is improved, but macrophage uptake and off-target effects increase
Solution Approach 1:
The patent introduces CD47 polypeptides as intermediary molecules that bind to the LNP surface and interact with SIRPα receptors on macrophages. This intermediary mechanism blocks the phagocytic recognition pathway, preventing macrophage uptake while preserving the LNP's delivery function to target cells
Solution Approach 2:
The patent modifies the surface properties of LNPs by conjugating CD47 polypeptides, changing the biochemical parameters of the particle surface. This parameter change alters the immune recognition profile, transforming the LNP from an immunogenic particle to one that evades macrophage detection through the CD47-SIRPα interaction
2Measurement precision
If LNPs are used for therapeutic delivery, then targeted delivery is improved, but off-target effects and inflammatory responses increase
Solution Approach 1:
CD47 polypeptides serve as protective intermediaries that shield the LNP from immune recognition. By engaging SIRPα receptors, they create a protective interaction that prevents inflammatory signaling pathways from being activated, reducing off-target inflammatory effects
Solution Approach 2:
The patent exploits the natural CD47-SIRPα interaction, which normally functions in cellular self-recognition and phagocytosis regulation. By harnessing this existing biological pathway, the invention converts a potential harmful immune response into a beneficial protective mechanism that reduces inflammation and off-target effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution significantly reduces non-specific uptake and off-target effects, increasing the proportion of therapeutic agents reaching targeted cells, reducing inflammatory responses, and minimizing hepatic delivery, thereby enhancing the safety and efficacy of RNA-based therapies.
Implementation Method 1
a moiety to inhibit uptake of the composition by a macrophage
Implementation Method 2
lipid nanoparticles (LNPs) are employed to pack RNA and protect cargo en route to the site of action
Implementation Method 3
a targeting moiety specific for binding to a target cell
Data Source
AI summary
The present invention relates to compositions and methods for effective delivery of a therapeutic agent to a subject using a delivery vehicle comprising a domain to evade the subject's immune response. In some embodiments, the present invention relates to compositions and methods for targeted delivery of a therapeutic agent to a subject using a delivery vehicle comprising a domain to evade the subject's immune response and a domain for targeting a specific cell type. The invention also relates to methods of use of the compositions of the invention for the treatment of diseases and disorders, including the treatment of diseases and disorders in subjects having an inflammatory or autoimmune disease or disorder.